For all press and media enquiries please contact mediarelations@chiesi.com
New HFA 152a production facility will produce low global warming potential (GWP) propellants for pressurised metered dose inhalers (pMDIs). The new propellant will reduce the carbon footprint of pMDI inhalers by up to 90%, down to a similar level as a dry powder inhaler (DPI). [1] New inhaler will…
On Monday 17 January, Chiesi had the honour of welcoming the Minister for Territorial Cohesion and Relations with Local Authorities, Ms Jacqueline Gourault, at its industrial site in La Chaussée Saint-Victor. Following the postponement of the Choose France summit due to the health situation, the…
The recommendations of an international expert panel to update the definition and severity classification of chronic obstructive pulmonary disease (COPD) exacerbations will be presented by Professor Bartolome R. Celli at the 2021 International Meeting on Asthma and COPD in Florence Physicians will…
The Biotech Center of Excellence Plant will be operational from 2024 The presentation event in Rome with the Italian Minister of Economic Development, Giancarlo Giorgetti Chiesi Group is entering into a constantly growing sector, confirming a corporate culture focused on the patient, at every stage…
The volume follows the project of the new, innovative, and sustainable headquarters of the Group, opened in Parma in June 2020 based on a project by EFA architectural studio Parma (Italy), December 13, 2021 – The Chiesi Headquarters in Parma, the international research-focused pharmaceutical and…
UCB has granted to Chiesi global exclusive rights to develop, manufacture, and commercialise zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases; Zampilimab complements Chiesi’s existing respiratory pipeline by adding a potential…
The Group’s R&D hub in Parma employs 638 people, 498 of whom are researchers, and currently has a total of 45 R&D projects underway; In 2020, Chiesi invested €448 million in R&D activities, representing more than 20% of its turnover; The building, which was officially opened in 2011, was recently…
Chiesi Group has received an ESG rating A with an overall ESG score of 73.7 out of 100 Cerved Rating Agency: “Chiesi is among the best performing companies in the Healthcare Products sector” Chiesi particularly stands out for environmentally friendly product innovation and employee well-being Parma…
Panel of experts calls for urgent policy action Climate change and its impact on lung health: a focus on Europe says climate change is damaging respiratory health in many ways not commonly known [1] In Europe, climate change is particularly affecting the vulnerable in society, but healthy people…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
